Chimerix, Inc. Appoints David Jakeman as Executive Director of Finance and Accounting Serving as its Principal Accounting Officer
June 21, 2019 at 04:06 pm EDT
Share
On June 20, 2019, the Board of Directors of Chimerix, Inc. appointed David Jakeman, CPA as the Company’s Executive Director of Finance and Accounting serving as the Company’s principal accounting officer, effective immediately. Mr. Jakeman has worked in various finance-related roles at the Company since 2009, most recently serving as the Company’s Director of Finance since January 2011. Prior to joining the Company, from 2000 to 2009, Mr. Jakeman worked at Ernst & Young LLP in their assurance practice.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
CHIMERIX, INC. 
